Brief: Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

Elicio Therapeutics

07/11/2025 14:08

Nov 7 (Reuters) - Elicio Therapeutics Inc ELTX.O:

ELICIO THERAPEUTICS REPORTS ROBUST, CYTOLYTIC MKRAS-SPECIFIC T CELL RESPONSES ACROSS DIVERSE PATIENT HLA IN ONGOING PHASE 2 AMPLIFY-7P TRIAL OF ELI-002 7P AND NEW ELI-004 PRECLINICAL DATA AT SITC

Source text: ID:nGNX7mMgb

Further company coverage: ELTX.O

 ((Reuters.Briefs@thomsonreuters.com;))